Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE: ELAN) has completed the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash. Net proceeds of $1.05-$1.1 billion from this transaction are earmarked for debt reduction in the third quarter of 2024. This move allows Elanco to focus on high-value opportunities in pet health and livestock sustainability, while also enhancing financial flexibility. This transaction, combined with cash flow from operations, is expected to reduce Elanco's total debt by $1.3-$1.4 billion by the end of 2024. The company's net debt to adjusted EBITDA ratio is projected to improve from mid-4x in 2024 to high-3x to low-4x in 2025. Additional details will be provided in the second quarter earnings call in August.

Elanco Animal Health has announced major updates regarding FDA approval timelines for two key products: Zenrelia and Credelio Quattro. Zenrelia has completed all major technical sections and expects final approval by late Q3 2024, with a U.S. launch in Q4 2024. However, a safety warning on the label is anticipated to limit initial adoption by 25%. Zenrelia has already been approved in Brazil with further reviews pending in other markets.

Credelio Quattro has completed two of three major technical sections, with a response to an incomplete letter for the third section already submitted. Final approval is expected in Q4 2024, with a U.S. launch in Q1 2025. Elanco has increased its 2024 innovation sales guidance to $400-$450 million, driven by expected launches and strong existing product performance.

On June 26, 2024, Elanco announced that the Food and Drug Administration (FDA) has approved Bovaer, a feed additive that reduces methane emissions in dairy cows by 30%. This approval marks a significant advancement in sustainable agriculture, as methane is a potent greenhouse gas. Bovaer, which is already used in several countries, works by inhibiting a gut enzyme responsible for methane production. Studies confirm that it has no negative health impacts on cows or humans. This initiative is part of Elanco's broader efforts to provide environmentally friendly solutions in animal health.

Elanco Animal Health (NYSE: ELAN) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11-12, 2024. Jeff Simmons, the President and CEO, will engage in a fireside chat on June 11 at 2:40 p.m. ET. The event will be webcast live, and a replay will be accessible for 30 days on Elanco's investor website.

Elanco Animal Health has announced the FDA's completion of a multi-year review of Bovaer, a methane-reducing feed ingredient for dairy cattle, confirming its safety and efficacy. Bovaer can reduce methane emissions by about 30%, creating new revenue streams for dairy farmers through carbon credits. Elanco has also expanded its agreement with dsm-firmenich to distribute Bovaer across North America, including Canada and Mexico. This innovation aims to support climate-neutral dairy farming and meet the increasing demand for sustainable products. Bovaer is expected to generate significant value for farmers and the environment, potentially addressing global warming concerns through reduced greenhouse gas emissions.

Elanco Animal Health (NYSE: ELAN) announced its participation in the Stifel 2024 Jaws and Paws Conference, scheduled for May 29, 2024. Todd Young, Elanco's Executive Vice President and CFO, will engage in a fireside chat at 8:00 a.m. ET. Interested parties can access a live audio webcast through the 'Events and Presentations' section of Elanco's investor website. Additionally, a replay of the webcast will be available for 30 days post-event.

Elanco Animal Health reported revenue of $1,205 million and net income of $32 million in the first quarter of 2024. Adjusted EBITDA was $294 million, with adjusted EPS of $0.34. The company updated its full-year 2024 financial guidance, expecting revenue of $4,460 to $4,515 million and adjusted EPS of $0.88 to $0.96.